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Abstract 
Objectives: To examine whether fewer PD patients use antidepressant medication, when they are 
first treated with a dopamine agonist compared to other PD medications. Previous studies have 
suggested that dopamine agonists have an antidepressant effect in PD patients.  
Methods: PD patients diagnosed in Denmark were identified using the National Hospital Register, 
and the diagnosis was confirmed by a review of the medical record. Antidepressant medication was 
assessed using the Danish National Prescription Registry. We used Cox proportional hazards 
regression to model the association between PD medications and time to antidepressant 
prescription. 
Results: Of the 1,181 patients 438, 468, and 275 were first treated with levodopa, dopamine 
agonists and MAO-B inhibitors respectively, and 164 (37 %), 138 (29 %), and 106 (39 %) of the 
patients received a prescription for antidepressant medication. There was no significant difference 
in the hazard ratios for antidepressant prescriptions. 
Conclusions: The type of PD medication first prescribed did not affect the subsequent use of 
antidepressants. 
 
 
 
 
 
 
 
 
 
Introduction 
Depression is one of the most important non-motor symptoms of idiopathic Parkinson’s disease 
(PD).  Depressed PD patients have reduced motor function and activities of daily living, exhibit 
more cognitive symptoms, and report lower quality of life than non-depressed patients. Clinical 
studies suggest that these consequences are reversible with adequate treatment, but depression is 
still underdiagnosed and undertreated in PD patients (1-3). The incidence of depression in newly 
diagnosed PD patients was approximately two-fold higher compared to non-PD controls in a 
follow-up study based on the UK-General Practice Research Database (4). A recent meta-analysis of 
studies assessing the prevalence of depression in PD patients reported that on average 35% of PD 
patients had depressive symptoms of clinical significance (5), and a diagnosis of major depression 
according to DSM criteria could be established in 7 to 19 %.  
In contrast to depression in non-PD patients, depression in PD-patients it is most likely 
caused by a combination of decreased levels of dopamine and acetylcholine, as well as serotonin 
(6). The hypothesis that dopaminergic deficiency plays a role in depression of PD patients has 
stimulated some to hypothesize that treatment with dopamine agonists might be effective against 
depression in PD patients, in addition to alleviating motor symptoms. This notion was supported by 
some clinical trials (7-8), but a recent review considered the data inconclusive (1). Interestingly, the 
dopamine agonist pramipexole to date is the only drug considered clinically useful for treatment of 
depressive symptoms in PD according to the Movement Disorders Society, whereas the efficacy of 
the widely used selective serotonin reuptake inhibitors (SSRIs) for PD depression is still 
controversial (9). Specifically, a placebo-controlled trial of the SSRI citalopram in PD showed no 
statistically significant difference between the drug and placebo treatment (10). However, a post hoc 
analysis found that approximately 70% of the patients in this trial suffered from Recurrent Brief 
Depression in accordance with ICD-10, which is more difficult to treat than major depression.  
The PASIDA study is a population-based case-control study of PD patients in Denmark 
treated at ten neurological departments and first identified using the National Hospital Register 
between 1996 and 2009, for whom the diagnosis of idiopathic PD has been confirmed by an 
extensive medical record review. We investigated the use of antidepressant medications in the 
PASIDA study population as reported in the Danish National Prescription Registry after 1995. We 
hypothesized that PD patients treated with a dopamine agonist first would be less likely to start 
using antidepressant medications compared to patients receiving treatment with levodopa or MAO-
B inhibitors as dopamine agonist use would supposedly reduce the necessity for additional 
pharmacological treatment of depression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
From among 1,814 patients with idiopathic PD identified from the registry between 1996 and 2009 
we excluded 240 patients, who already received PD medications prior to the date when the National 
Prescription Registry was established in 1995, 5 patients who never used PD medications according 
to the register, 51 patients who received their first prescription of PD medications prior to the onset 
of motor symptoms according to their medical record, and 337 patients who had received 
prescriptions of antidepressant medication prior to the prescription of PD medication. We used Cox 
proportional hazards regression to model associations between typical medications prescribed for 
Parkinson’s disease symptoms and time to first SSRI or a tricyclic antidepressant prescription 
during the follow-up period. Age was used as the underlying time scale and follow-up was from age 
at first prescription of PD medications after January 1st, 1997 until prescription of an antidepressant 
medication, death, emigration or end of study period at December 31st, 2011, whichever came first. 
PD medications were defined as: Levodopa (ATC codes N04BA02 and N04BA03), agonists (ATC 
codes N04BC02, N04BC04 (Ropinirole), N04BC05 (Pramipexole), N04BC07, and N04BC09 
(Rotigotine)) and MAO-B inhibitors (ATC codes N04BD01 and N04BD02).  Antidepressants were 
defined by ATC codes N06AA (tricyclic antidepressants), N06AB (SSRIs), and N06AX 
(noradrenaline reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors, and 
noradrenergic and specific serotonergic antidepressants).  
 
 
 
 
 
 
Results 
Among the 1,181 patients we followed, 438 patients were treated first with levodopa, and 468 and 
275 with an agonist or a MAO-B inhibitor, respectively. 84, 73, and 69 per cent of the patients were 
older than 55 years at the onset of motor symptoms, and 58, 65, and 63 per cent of the patients were 
males in each of these treatment groups. Mean time on monotherapy was 1.8, 1.1, and 0.9 years for 
levodopa, agonist, and MAO-B inhibitor treated patients respectively. The mean follow-up time was 
8.8, 7.1, and 9.3 years in the respective groups. No difference in the time to first prescription of an 
antidepressant was observed between patients who were first treated with levodopa, dopamine 
agonists, and MAO-B inhibitors (table 1). Separate analyses for each of the dopamine agonists 
pramipexole, ropinerole, and rotigotine also showed no effect on the subsequent use of 
antidepressants. Furthermore no differences were found in subgroups of patients defined by sex and 
age (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
This study based on long-term follow-up of a relatively large number of PD patients was not able to 
show any difference in the use of anti-depressant medications using a Cox proportional hazards 
regression analysis. The most important limitation to this study is the fact that we are not able to 
assess the number of patients diagnosed with a clinically significant depression in our study 
population. The prescription patterns among the treating physicians might be influenced by other 
factors than depressive symptoms in the PD patients including the use of other medications such as 
PD medications with proposed antidepressant effects such as pramipexole or the use of MAO-B 
inhibitors, which are not recommended for use with SSRIs due to drug interaction problems. 
Furthermore, SSRIs are prescribed for other conditions than depressions including neuropathic pain, 
anxiety disorders, and obsessive-compulsive disorders. Another important limitation is the fact that 
a second PD medication was added after a relatively short duration, making it difficult to assess the 
effect of a single PD medication alone on the need for an anti-depressant medication.  
The strength of the study is that it reflects the current clinical practice regarding the use of 
PD medications and treatment of depression in PD patients in a field of research where previous 
clinical studies have been sponsored by a drug manufacturer and have not focused specifically on 
depression (1). There is a need for future randomized controlled clinical trials to examine this 
hypothesis. 
In conclusion, we were not able to confirm that treatment with a dopamine agonist delays 
time to antidepressant medication use compared to treatment with levodopa or MAO-B inhibitors in 
PD patients based on the PASIDA study population and the Danish National Prescription Registry.  
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 Figure S1. Time from taking the first to taking a second drug 
 
Table 1 Demographic data, duration on PD drug monotherapy, and length of follow-up 
First PD 
medicatio
n 
n 
 
Sex 
(% 
male) 
Age at first 
symptom 
>= 55 years 
(%) 
Time on 
monotherapy – non-
AD initiators/[BR1]AD 
initiators 
(mean in years) 
Follow-up period –  
non-AD initiators/AD 
initiators (mean in 
years) 
Levodopa 438 58 84 1.7/1.9 8.8/4.3 
Agonists 468 65 73 1.1/1.1 7.1/3.9 
MAO-B 275 63 69 0.9/0.8 9.3/5.7 
Total 1181 62 76  8.2/4.5 
AD: Antidepressant medication. 
 
Table 2 Hazard ratio (and 95% CI) for time to first anti-depressant medication prescription 
according to type of first PD medication prescribed 
  Any antidepressant  SSRI  Tricyclic antidepressant 
 ntotal nantidepressant HR (95% CI) 
 
nSSRI HR (95% CI) 
 nTC
A 
HR (95% CI) 
Levodopa 438 164 1.00 -  96 1.00 -  45 1.00 - 
Agonists  468 138 0.95 
(0.75-
1.20) 
 
86 1.00 (0.74-1.34) 
 
25 0.61 (0.37-1.00) 
 Pramipexole 234 66 0.95 
(0.71-
1.27) 
 
43 1.05 (0.73-1.51) 
 
10 0.51 (0.25-1.00) 
  Ropinirole  121 29 0.92 
(0.82-
1.38) 
 
14 0.74 (0.42-1.30) 
 
9 1.04 (0.51-2.15) 
  Rotigotine  7 2 - -  2 - -  0 - - 
  Other types  106 41 0.95 
(0.67-
1.35) 
 
27 1.06 (0.68-1.63) 
 
6 0.49 (0.21-1.15) 
MAO-B  275 106 0.97 
(0.76-
1.26) 
 
60[BR2] 0.92 (0.66-1.29) 
 
30 0.97 (0.60-1.57) 
 
TCA: Tricyclic antidepressant 
 
Table 3 Hazard ratio (and 95% CI) for first antidepressant medication prescription according to 
type of first PD medication used by sex and age 
 Sex  Age at first symptom 
 Men  Women  < 55 years  ≥ 55 years 
 HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI) 
Levodopa 1.00 -  1.00 -  1.00 -  1.00 - 
Agonists  0.99 (0.71-1.36)  0.94 (0.67-1.32)  0.97 (0.59-1.60)  0.93 (0.71-1.22) 
MAO-B  1.09 (0.77-1.54)  0.87 (0.60-1.27)  0.83 (0.49-1.40)  1.02 (0.76-1.37) 
            
            
 
 
 
